G. Coteur

Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study

Robert Landewé, Jürgen Braun, Atul Deodhar et al. · Annals of the Rheumatic Diseases · 2013 · 462 citations · Full text

Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study

Roy Fleischmann, Jiří Vencovský, Ronald van Vollenhoven et al. · Annals of the Rheumatic Diseases · 2008 · 333 citations · Full text

Certolizumab Pegol for Active Crohn's Disease: A Placebo-Controlled, Randomized Trial

William J. Sandborn, Stefan Schreiber, Brian G. Feagan et al. · Clinical Gastroenterology and Hepatology · 2011 · 166 citations

Pharmacology, Gastroenterology, Clinical Gastroenterology +4

Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab′ certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension

Kristian Reich, J.‐P. Ortonne, Alice B. Gottlieb et al. · British Journal of Dermatology · 2012 · 155 citations

Evaluation of the meaningfulness of health‐related quality of life improvements as assessed by the SF‐36 and the EQ‐5D VAS in patients with active Crohn’s disease

G. Coteur, Brian G. Feagan, Dorothy L. Keininger et al. · Alimentary Pharmacology & Therapeutics · 2009 · 133 citations · Full text